Mycophenolic acid area under the curve recovery time following rifampicin withdrawal
Authors:
Open Access
- 1 January 2010
- journal article
- case report
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 20 (1) , 51-3
Abstract
Renal transplant patients prescribed mycophenolate mofetil (MMF) may require treatment for tuberculosis with a regimen including the tuberculocidal drug rifampicin. MMF is an ester prodrug which is rapidly hydrolysed to the active compound, mycophenolic acid (MPA). Therapeutic drug monitoring of mycophenolate involves the measurement of MPA area under the curve (MPA-AUC 0-12 ). Rifampicin is known to increase the metabolism and decrease enterohepatic recirculation of mycophenolic acid, (MPA). When MPA is monitored after the discontinuation of rifampicin, an important factor is the time required for the MPA area under the curve to return to the pre-rifampicin value. At present this is not known. This report describes one such renal allograft patient, on long term MMF and prescribed rifampicin by a local physician. As expected there was a clinically significant decrease in MPA-AUC 0-12 . Three weeks after rifampicin was discontinued the MPA-AUC 0-12 was still only 65% of the pre-rifampicin value and only 55% of the steady state MPA-AUC 0-12 measured six months later.Keywords
This publication has 9 references indexed in Scilit:
- A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent.2006
- Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipientsClinical Pharmacology & Therapeutics, 2006
- Within-Patient Variability of Mycophenolic Acid ExposureTherapeutic Drug Monitoring, 2006
- Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferaseClinical Pharmacology & Therapeutics, 2005
- Early Adequate Mycophenolic Acid Exposure is Associated with Less Rejection in Kidney TransplantationAmerican Journal of Transplantation, 2004
- Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring StrategiesAmerican Journal of Transplantation, 2003
- Monitoring of Mycophenolic Acid in Clinical TransplantationTherapeutic Drug Monitoring, 2002
- Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable DiscussionTherapeutic Drug Monitoring, 2001
- Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomesBritish Journal of Pharmacology, 2001